This new formula designated mRNA-1273.214is a “bivalent” vaccineso it acts both against the original virus and against the omicron variant.
With this dose, antibodies against the most recent strain increased eightfold, according to the company, which anticipates that this vaccine will provide “prolonged protection against variants of concern” of the coronavirus, Moderna CEO Stéphane Bancel said.
“We are submitting our preliminary data and analysis to regulators, with the expectation that our bivalent booster (…) will be available by the end of the boreal summer”he added.
Currently, all vaccines in circulation are based on the original strain of the virus and have been shown to be less effective against variants that have emerged.
The US drug agency (FDA) plans to convene a committee in late June to assess whether the virus strain used to develop current vaccines “should be changed and, if so, which strain(s) should be selected for use.” fall 2022,” according to the agency.
Latest news on Covid-19
Patients with blood cancers have a significantly weaker antibody response to immunization than patients with solid tumors, but may be well protected against severe disease, researchers reported at ASCO 2022, the annual meeting of the American Society of Cancer. Clinical Oncology.
Researchers at Monash University in Australia studied immune responses after three doses of Moderna, Pfizer/BioNTech, or AstraZeneca COVID vaccines in nearly 400 adults with active or recently treated cancers.
They found that only 3.2% of 256 patients with solid tumors lacked antibodies capable of neutralizing SARS-CoV-2 and preventing infection, compared to 30% of 137 with hematologic malignancies. However, T cell responses were similar regardless of cancer type.
Thus, T-cell responses may indicate immune protection “for those who do not have an antibody response,” the researchers noted.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
